A Clinical Trial to study the effect of two drugs Vortioxetine and Escitalopram in patients of Depression.

A comparative study of Vortioxetine and Escitalopram in Depression.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/029949

Enrollment

Registered

2020-12-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F330- Major depressive disorder, recurrent, mild

Interventions

Intervention1: Vortioxetine 10mg OD: Vortioxetine 10mg HS orally for 8 weeks Control Intervention1: Escitalopram 10mg: Escitalopram 10mg HS orally for 8 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of depression as per ICD-10 HDRS score more than 12 willing to give written informed consent

Exclusion criteria

Exclusion criteria: Patients with pre-existing sexual dysfunction or cognitive dysfunction independent of depression Patients with any major medical or surgical illness Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Change in HAM-D, HAM-A, SOFAS, PGI BBD-Memory scale scoresTimepoint: baseline, 4 and 8 weeks	—

Secondary

Measure	Time frame
Change in sexual functioningTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Pragya Jain

King Georges Medical University

nischal.anuradha@gmail.com8960718000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026